OCA
SNDX icon

Octagon Capital Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Octagon Capital Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-904,000
Closed -$11.1M – 34
2025
Q1 		$11.1M Hold
904,000
– – 2.15% 19
2024
Q4 		$12M Buy
+904,000
New +$15.5M 1.97% 22

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Octagon Capital Advisors's SNDX Position: Q2 2025 in Review

Octagon Capital Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 904,000 shares — an estimated $11.1M sold.

Octagon Capital Advisors first reported a position in SNDX in Q4 2024 and held it in 2 quarters. The position peaked at $12M in Q4 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • Octagon Capital Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 904,000 Syndax Pharmaceuticals shares in Q2 2025, an estimated $11.1M.
  • Octagon Capital Advisors first reported a position in Syndax Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Octagon Capital Advisors's Syndax Pharmaceuticals position peaked at $12M in Q4 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on Octagon Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.